How many nanoparticle-based drugs reach tumours? Less than one percent, study shows
Wednesday, April 27, 2016 - 06:20
in Mathematics & Economics
Targeting cancer cells for destruction while leaving healthy cells alone—that has been the promise of the emerging field of cancer nanomedicine. But a new meta-analysis from U of T's Institute of Biomaterials & Biomedical Engineering (IBBME) indicates that progress so far has been limited and new strategies are needed if the promise is to become reality.